European biotech and clinical-research figures broadly agree with nine major drugmakers whose chairs signed a letter urging governments to reward new medicines better, but say the fixes go well beyond price.
Tag Archive for: biopharma innovation
lkov - adobe stock photoNovartis AG has reported a clinical milestone in the treatment of Sjögren’s syndrome, with its BAFF receptor blocker Ianalumab (VAY736) becoming the first investigational therapy to demonstrate a statistically significant reduction in disease activity in pivotal Phase III trials, as measured by the ESSDAI score.